Merck’s antibiotic ZERBAXA® (ceftolozane and tazobactam) has met its primary endpoint of non-inferiority compared with meropenem in a Phase III trial of patients with hospital-acquired and ventilator-associated bacterial pneumonia.
Browsing: Disease Area > Bacterial
Scientists at the University of Manchester (UK) have developed the first non-antibiotic drug to successfully treat tuberculosis (TB) in animal…
In this interview, take a look behind the scenes of a recent Future Microbiology paper on antibiotic resistance targets for point-of-care diagnostics with author, John P. Hays.
Financial modelling has been used to estimate the costs and likelihood of candidate medicines, vaccines, diagnostics and technologies launching, revealing gaps in the pipeline and in funding.
The European Gonococcal Antimicrobial Surveillance Programme has revealed high levels of azithromycin resistance in Europe, however, these have remained relatively stable.
From antibiotic susceptibility testing to new instruments to screen for antibiotics, 3D printing is contributing to research on antimicrobial resistance.
Continuous mass distribution of azithromycin in northern Ethiopia is effective for trachoma prevention but doesn’t eliminate the disease entirely, according to new research.
Researchers from the Okinawa Institute of Science and Technology have developed a method to study biofilm formation, and how it is affected by drugs, with high efficacy.